专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004031413A3 METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS 审中-公开
标题翻译：诊断非小细胞肺癌的方法
公开(公告)号：WO2004031413A3
公开(公告)日：2005-02-24
申请号：PCT/JP0312072
申请日：2003-09-22
申请人： ONCOTHERAPY SCIENCE INC , JAPAN AS REPRESENTED BY THE PR , NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
IPC分类号： A61P35/00 , C12N15/113 , C12N15/12 , C12Q1/68 , A61K39/00 , C12N15/11 , G01N33/50
CPC分类号： G01N33/57423 , A61K31/7088 , C07K14/47 , C12N15/1135 , C12N2310/11 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , G01N2800/50
摘要： Disclosed are methods for detecting non-small cell lung cancer using differentially expressed genes. Furthermore, novel human genes whose expression is elevated in non-small cell lung cancer compared to no-cancerous tissues are provided. Also disclosed are methods of identifying compounds for treating and preventing non-small cell lung cancer.
摘要翻译：公开了使用差异表达基因检测非小细胞肺癌的方法。此外，提供了与非癌性组织相比在非小细胞肺癌中表达升高的新型人类基因。还公开了鉴定用于治疗和预防非小细胞肺癌的化合物的方法。

2. 发明申请

WO2004031231A3 GENES AND POLYPEPTIDES RELATING TO PROSTATE CANCERS 审中-公开
标题翻译：与前列腺癌相关的基因和多肽
公开(公告)号：WO2004031231A3
公开(公告)日：2004-07-08
申请号：PCT/JP0312074
申请日：2003-09-22
申请人： ONCOTHERAPY SCIENCE INC , JAPAN AS REPRESENTED BY THE PR , NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
IPC分类号： C07K14/47 , C12Q1/68
CPC分类号： C07K14/47 , C12Q1/6886 , C12Q2600/136
摘要： The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.
摘要翻译：本申请提供了新型人基因MICAL2-PV，其表达在前列腺癌中显着升高。此外，它提供由该基因编码的多肽以及由PCOTH编码的多肽，其表达也被发现在前列腺癌中升高。由该基因编码的基因和多肽可以用于例如前列腺癌的诊断中，作为用于开发针对该疾病的药物的靶分子，以及用于减轻前列腺癌的细胞生长。

3. 发明申请

WO2004031414A3 METHOD FOR DIAGNOSING PROSTATE CANCER 审中-公开
标题翻译：诊断前列腺癌的方法
公开(公告)号：WO2004031414A3
公开(公告)日：2004-07-08
申请号：PCT/JP0312073
申请日：2003-09-22
申请人： ONCOTHERAPY SCIENCE INC , JAPAN AS REPRESENTED BY THE PR , NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
IPC分类号： C07K14/47 , C12Q1/68
CPC分类号： C07K14/47 , C12Q1/6886 , C12Q2600/136
摘要： Objective methods for detecting and diagnosing prostate cancer (PRC) or prostatic intraepithelial neoplasia (PIN) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of PRC -associated gene that discriminate between PRC or PIN and nomal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of either or both of PRC and PIN, methods of treating either or both of PRC and PIN and method of vaccinating a subject against either or both of PRC and PIN.
摘要翻译：本文描述了用于检测和诊断前列腺癌（PRC）或前列腺上皮内瘤变（PIN）的客观方法。在一个实施方案中，诊断方法涉及确定区分PRC或PIN和正常细胞的PRC相关基因的表达水平。本发明还提供筛选用于治疗PRC和PIN中的任一者或两者的治疗剂的方法，治疗PRC和PIN中的任一者或两者的方法以及针对PRC和PIN中的任一者或两者接种受试者的方法。

4. 发明申请

WO2007013480A2 SCREENING AND THERAPEUTIC METHOD FOR NSCLC TARGETING CDCA1-KNTC2 COMPLEX 审中-公开
标题翻译：非小细胞肺癌靶向CDCA1-KNTC2复合物的筛选和治疗方法
公开(公告)号：WO2007013480A2
公开(公告)日：2007-02-01
申请号：PCT/JP2006314715
申请日：2006-07-19
申请人： ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
IPC分类号： G01N33/574 , A61K47/46 , A61P35/00
CPC分类号： G01N33/57423 , G01N2500/02
摘要： The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.
摘要翻译：本发明基于观察到CDCA1和KNTC2的共激活及其同源相互作用在肺癌发展中起重要作用，抑制复合物的方法可用于治疗非小细胞肺癌。

5. 发明申请

WO2007116923A2 SEZ6L2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER 审中-公开
标题翻译： SEZ6L2 ONCOGENE作为肺癌的治疗目标和预防指标
公开(公告)号：WO2007116923A2
公开(公告)日：2007-10-18
申请号：PCT/JP2007057620
申请日：2007-03-29
申请人： ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
IPC分类号： C12N15/113
CPC分类号： C12N15/1138 , C12N2310/111 , C12N2310/14 , G01N33/57423 , G01N2500/02
摘要： The present invention provides a method for assessing the prognosis of non-small cell lung cancer (NSCLC) using SEZ6L2, as well as methods for evaluating the efficacy of a particular therapy for NSCLC. In addition, the present invention provides kits for prognosing NSCLC. Furthermore, treatment of NSCLC cells with vector-based small interfering RNAs (siRNAs) against the SEZ6L2 gene suppressed its expression and resulted in growth suppression of the NSCLC cells. These results indicate that SEZ6L2 may be useful as a diagnostic marker and as a target for development of new molecular therapies for lung cancer.
摘要翻译：本发明提供了一种使用SEZ6L2评估非小细胞肺癌（NSCLC）的预后的方法，以及用于评价特定治疗NSCLC的疗效的方法。此外，本发明提供了用于预测NSCLC的试剂盒。此外，针对SEZ6L2基因的基于载体的小干扰RNA（siRNA）治疗NSCLC细胞抑制其表达，并导致NSCLC细胞的生长抑制。这些结果表明，SEZ6L2可能作为诊断标记和作为肺癌新型分子疗法开发的目标是有用的。

6. 发明申请

WO2005090603A3 METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER 审中-公开
标题翻译：用于诊断非小细胞肺癌的方法
公开(公告)号：WO2005090603A3
公开(公告)日：2006-03-02
申请号：PCT/JP2005005613
申请日：2005-03-18
申请人： ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
IPC分类号： C12Q1/68 , A61K31/731
CPC分类号： A61K31/731 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
摘要翻译：公开了使用差异表达基因KIF11，GHSR1b，NTSR1和FOXM1检测非小细胞肺癌（NSCLC）的方法。还公开了基于KOC1和KIF11或NMU和GHSR1b或NTSR1之间的相互作用鉴定用于治疗和预防NSCLC的化合物的方法。

7. 发明申请

WO2008023840A2 PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR LUNG CANCER 审中-公开
标题翻译：预测肺癌的预后指标和治疗目标
公开(公告)号：WO2008023840A2
公开(公告)日：2008-02-28
申请号：PCT/JP2007066825
申请日：2007-08-23
申请人： ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention provides a diagnostic marker to detecting lung cancer. In particular, the present invention provides lung cancer marker genes i.e. KIF4A, MAPJD, NPTX, or FGFR1OP. The present invention further provides methods and kit for identifying compounds for treating lung cancer as well as methods for predicting a prognosis or diagnosis of lung cancer. In particular, the present invention provides methods and kits for identifying inhibitors of the interaction between KIF4A/ZNF549, KIF4A/ZNF553, MAPJD/MYC, or FGFR1OP/WRNIP1 which find utility in the treatment and prevention of lung. Alternatively, the present invention provides MAPJD associated with HAT complex as therapeutic target.
摘要翻译：本发明提供了检测肺癌的诊断标记。具体而言，本发明提供肺癌标志物基因，即KIF4A，MAPJD，NPTX或FGFR1OP。本发明进一步提供了鉴定用于治疗肺癌的化合物的方法和试剂盒以及预测肺癌预后或诊断的方法。具体而言，本发明提供了用于鉴定可用于治疗和预防肺的KIF4A / ZNF549，KIF4A / ZNF553，MAPJD / MYC或FGFR1OP / WRNIP1之间相互作用抑制剂的方法和试剂盒。或者，本发明提供与作为治疗靶标的HAT复合物相关的MAPJD。

8. 发明申请

WO2007013665A3 METHOD OF DIAGNOSING SMALL CELL LUNG CANCER 审中-公开
标题翻译：诊断小细胞肺癌的方法
公开(公告)号：WO2007013665A3
公开(公告)日：2007-07-05
申请号：PCT/JP2006315254
申请日：2006-07-26
申请人： ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
IPC分类号： C12Q1/68 , C12N15/113
CPC分类号： C12N15/1135 , C12N2310/14 , C12Q1/6886 , C12Q2600/136
摘要： Objective methods for detecting and diagnosing small cell lung cancer (SCLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that distinguishes two major histological types of lung cancer, non-small cell lung cancer (NSCLC) and SCLC. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of small cell lung cancer, methods of treating small cell lung cancer and method for vaccinating a subject against small cell lung cancer. Furthermore, the present invention provides chemotherapy resistant lung cancer- or SCLC-associated genes as diagnostic markers and/or molecular targets for therapeutic agent for these cancers. These genes are up-regulated in chemoresistant lung cancer or SCLC. Accordingly, chemoresistant lung cancer or SCLC can be predicted using expression level of the genes as diagnostic markers. As the result, any adverse effects caused by ineffective chemotherapy can be avoided, and more suitable and effective therapeutic strategy can be selected.
摘要翻译：本文描述了用于检测和诊断小细胞肺癌（SCLC）的客观方法。在一个实施方案中，诊断方法包括确定区分SCLC细胞和正常细胞的SCLC相关基因的表达水平。在另一个实施方案中，诊断方法涉及确定区分肺癌，非小细胞肺癌（NSCLC）和SCLC两种主要组织学类型的SCLC相关基因的表达水平。最后，本发明提供筛选用于治疗小细胞肺癌的治疗剂的方法，治疗小细胞肺癌的方法和用于针对小细胞肺癌接种受试者的方法。此外，本发明提供化疗耐受性肺癌或SCLC相关基因作为这些癌症的治疗剂的诊断标记和/或分子靶标。这些基因在化学抗性肺癌或SCLC中上调。因此，可以使用基因的表达水平作为诊断标记来预测化学抗性肺癌或SCLC。结果，可以避免由无效化疗引起的任何副作用，并且可以选择更合适和有效的治疗策略。

9. 发明申请

WO2007013671A2 METHOD OF DIAGNOSING ESOPHAGEAL CANCER 审中-公开
标题翻译：诊断食管癌的方法
公开(公告)号：WO2007013671A2
公开(公告)日：2007-02-01
申请号：PCT/JP2006315342
申请日：2006-07-26
申请人： ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , Y10T436/25
摘要： In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, a Homo sapiens epithelial cell transforming sequence 2 oncogene (ECT2) and a cell division cycle 45, S. cerevisiae, homolog-like (CDC45L) are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. Furthermore, the present inventors have identified DKK1 as a potential biomarker for diagnosis of cancer such as lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKK1 was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKK1, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this molecule is also a likely candidate for development of therapeutic approaches such as antibody therapy.
摘要翻译：为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗目标的分子，构建了代表32,256个基因的cDNA微阵列，分析了19例食管鳞状细胞癌（ESCCS）的表达谱）通过激光捕获显微切割纯化。本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。此外，本文公开了与淋巴结转移和手术后复发相关的基因。在候选分子靶基因中，进一步表征了人类上皮细胞转化序列2致癌基因（ECT2）和细胞分裂周期45，酿酒酵母，同系物样（CDC45L）。用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。此外，本发明人鉴定了DKK1作为肺癌，食管癌等癌症诊断用潜在生物标志物，并预测了这些疾病患者的预后差。本发明人检查的大多数肺癌和食管癌组织中DKK1被特异性过度表达，并且在大量患有这些肿瘤的患者的血清中升高。 DKK1与其他肿瘤标志物结合可显着提高癌症诊断的敏感性。此外，该分子也是开发抗体治疗等治疗方法的可能候选者。

10. 发明申请

WO2008072777A3 TTK AS TUMOR MARKER AND THERAPEUTIC TARGET FOR LUNG CANCER 审中-公开
标题翻译： TTK作为肿瘤标志物和肺癌的治疗目标
公开(公告)号：WO2008072777A3
公开(公告)日：2008-07-31
申请号：PCT/JP2007074359
申请日：2007-12-12
申请人： ONCOTHERAPY SCIENCE INC , NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
发明人： NAKAMURA YUSUKE , DAIGO YATARO , NAKATSURU SHUICHI
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed herein is a method for determining kinase activity of TTK for EGFR and methods of screening for modulators of this kinase activity. Also disclosed are methods and pharmaceutical compositions for preventing and/or treating lung cancer that use or include such modulators. Methods for diagnosing lung cancer using the kinase activity of TTK for EGFR protein as an index as well as methods for assessing and prognosing lung cancer are also provided.
摘要翻译：本文公开了确定EGFR的TTK的激酶活性的方法和筛选该激酶活性的调节剂的方法。还公开了用于预防和/或治疗使用或包括这种调节剂的肺癌的方法和药物组合物。还提供了使用TTK对EGFR蛋白的激酶活性作为指标诊断肺癌的方法以及肺癌的评估和预后的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式